A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

Protocol No
IOVANCE-IOV-COM-202
Principal Investigator
Smitha Menon
Phase
II
Summary
The purpose of this clinical research study is to find out if an Investigational Product/Investigational Drug called LN-144/LN-145 is safe and beneficial in the treatment of patients with Metastatic Melanoma or HNSCC when given in combination with a medication named pembrolizumab (Keytruda®) or in patients with NSCLC, when LN-144/LN-145 is given alone as a single therapy.
Description
Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: